Announcements Trials
Browse Landscape

Phase

Phase 1 35Phase NA 34Phase 2 29Phase EARLY_PHASE1 8Phase 4 5Phase 3 4Phase 1/2 4

Status

Completed 58Unknown 20Recruiting 16Active not recruiting 13Terminated 6Not yet recruiting 6Withdrawn 4Enrolling by invitation 2Suspended 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 34Genitourinary 29Breast 25Thoracic 23Lymphoid 22Other hematologic neoplasm 15Gynecologic 14Head & Neck 10CNS 8Sarcoma 5Dermatologic 5Tumor-Agnostic 4Plasma cell 4Myeloid 3Endocrine 3Classical hematology 3Other solid neoplasm 1Other neoplasm 1Other 1NET 1

Conditions

Neoplasms 2Neoplasm Metastasis 1Adenocarcinoma 1

Interventions

pertuzumab 1Vinorelbine 1Trastuzumab 1Radiotherapy, Intensity-Modulated 1Heavy Ion Radiotherapy 1Glutamine 1Docetaxel 1Atomoxetine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Withdrawn × Tumor-Agnostic × Clear all
NCT00255138 2022-04-01

Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects

Temple University

Phase 3 Withdrawn
Tumor-Agnostic

Neoplasms

NCT03536182 2021-05-26

CIPHER

University of Texas Southwestern Medical Center

Phase 3 Withdrawn
Tumor-Agnostic

Adenocarcinoma

NCT03811418 2019-11-26

ATTILA

iOMEDICO AG

Phase 3 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

NCT01032512 2018-02-19

Clinical Benefits of Preoperative Nutrition Support With Enteral Immune-enhancing Formulas in Surgical Oncology

University of Chile

Phase 3 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡